AI-powered CCTA outperforms usual care when evaluating stable chest pain

Overall, the use of CCTA and FFR-CT was associated with three key benefits compared to stress testing and ICA: improved accuracy, fewer unnecessary tests, and increased confidence.

HeartFlow issued a prepared statement about these findings as soon as they were shared with the public.

“This is the strongest level of scientific evidence yet to support the approach professional guidelines recommending that physicians use to diagnose stable chest pain patients,” study chair Pamela Douglas, MD, the Ursula Geller Professor for Research in Cardiovascular Disease at Duke University School of Medicine , said in the statement. “Combining multiple steps into a precision pathway provides a clear path forward for clinicians.”

“We’re pleased to see these data support what the guidelines already recognize,” added Campbell Rogers, MD, HeartFlow’s chief medical officer. “We believe this level-one clinical science information will be used by more practitioners to guide decisions on how to optimize care for people with suspected coronary artery disease.”


Source link

Leave a Comment

Your email address will not be published.